Patents by Inventor Jason Grant Kettle
Jason Grant Kettle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10519152Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.Type: GrantFiled: December 18, 2018Date of Patent: December 31, 2019Assignee: AstraZeneca ABInventors: Bin Yang, Jason Grant Kettle, Thomas George Christopher Hayhow, Timothy Gordon Rasmusson, Johannes Wilhelmus Maria Nissink, Charlene Fallan, Gillian McGregor Lamont
-
Publication number: 20190367490Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.Type: ApplicationFiled: January 16, 2018Publication date: December 5, 2019Applicant: AstraZeneca ABInventors: Karl Magnus NILSSON, Annika Birgitta Margareta ASTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTO, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
-
Publication number: 20190194190Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: December 18, 2018Publication date: June 27, 2019Inventors: Bin YANG, Jason Grant KETTLE, Thomas George Christopher HAYHOW, Timothy Gordon RASMUSSON, Johannes Wilhelmus Maria NISSINK, Charlene FALLAN, Gillian McGregor Lamont
-
Publication number: 20190177338Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: December 6, 2018Publication date: June 13, 2019Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
-
Publication number: 20190092760Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 20, 2018Publication date: March 28, 2019Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Patent number: 10167276Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 22, 2017Date of Patent: January 1, 2019Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika Astrand, Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
-
Publication number: 20170320857Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 22, 2017Publication date: November 9, 2017Applicant: AstraZeneca ABInventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Patent number: 9714236Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 22, 2016Date of Patent: July 25, 2017Assignee: ASTRAZENECA ABInventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
-
Publication number: 20170088543Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 22, 2016Publication date: March 30, 2017Applicant: AstraZeneca ABInventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, Dedong WU, Wenzhan YANG, Tudor GRECU, James MCCABE
-
Patent number: 8399667Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.Type: GrantFiled: February 16, 2010Date of Patent: March 19, 2013Assignee: Astrazeneca ABInventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
-
Publication number: 20130005727Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.Type: ApplicationFiled: September 10, 2012Publication date: January 3, 2013Applicant: ASTRAZENECA ABInventors: Robert Hugh BRADBURY, Laurent Francois Andre HENNEQUIN, Jason Grant KETTLE
-
Patent number: 7947676Abstract: The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.Type: GrantFiled: December 12, 2005Date of Patent: May 24, 2011Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
-
Publication number: 20110046108Abstract: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.Type: ApplicationFiled: January 25, 2007Publication date: February 24, 2011Applicant: AstraZeneca ABInventors: Jason Grant Kettle, Jon Read, Andrew Leach, Bernard Christophe Barlaam, Richard Ducray, Christine Marie Paul Lambert-Van Der Brempt
-
Publication number: 20100152442Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.Type: ApplicationFiled: February 16, 2010Publication date: June 17, 2010Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
-
Patent number: 7718653Abstract: A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic ring which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.Type: GrantFiled: July 16, 2008Date of Patent: May 18, 2010Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
-
Patent number: 7625908Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.Type: GrantFiled: November 11, 2004Date of Patent: December 1, 2009Assignee: AstraZeneca ABInventors: Laurent Francois Andre Hennequin, Robert Hugh Bradbury, Jason Grant Kettle
-
Publication number: 20090203663Abstract: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: February 7, 2007Publication date: August 13, 2009Applicant: AstraZeneca ABInventors: Jean Claude Arnould, Benedicte Delouvrie, Jason Grant Kettle
-
Publication number: 20090137601Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: November 22, 2006Publication date: May 28, 2009Applicant: ASTRAZENECA ABInventors: Simon Thomas Barry, Jason Grant Kettle, David Alan Rudge
-
Publication number: 20090023719Abstract: A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.Type: ApplicationFiled: July 16, 2008Publication date: January 22, 2009Applicant: Astrazeneca ABInventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
-
Publication number: 20080269487Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.Type: ApplicationFiled: June 26, 2008Publication date: October 30, 2008Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle